BioPharmX (BPMX) Reports Q1 Loss of $0.08/Share, Explores Funding Alternatives

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to BioPharmX (BPMX) Reports Q1 Loss of $0.08/Share, Explores Funding Alternatives

BioPharmX Reports First Quarter 2018 Financial Results

June 13, 2017 4:05 PM EDT

MENLO PARK, Calif., June 13, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, today announced its financial results for the first quarter ended April 30, 2017 and discussed the progress of its clinical research.

"The start of our year has been defined by steady achievement in clinical research, growing dermatology community interest in BPX-01, our investigational topical drug for acne, and careful management of resources," said President Anja Krammer. "The enthusiasm investigators expressed about our phase... More